Polsinelli advised SpyGlass Pharma, Inc., a clinical-stage ophthalmology-focused biotechnology company, on intellectual property matters in connection with its initial public offering of common stock. SpyGlass Pharma shares are traded on the Nasdaq Global Market under the ticker symbol “SGP.” More information about the offering can be found here.

SpyGlass Pharma is dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained-release drug delivery of approved therapeutics. One of the company’s missions is to significantly improve the lives of patients with chronic eye conditions by implementing long-lasting drug delivery solutions that can empower patients and surgeons with confidence in long-term eye condition progression prevention, control and overall vision preservation.

The SpyGlass Pharma platform includes a novel, non-bioerodible drug delivery technology that is designed to be used with various well-established, approved therapeutics, including bimatoprost and other molecules, providing flexibility to potentially treat a wide range of conditions in the front and back of the eye.

The Polsinelli team advised SpyGlass Pharma on intellectual property matters for several years leading up to and in connection with the offering and was led by Shareholders Roberta J. Hanson, Ph.D. and Josh J. Pranckun and included Shareholder and Intellectual Property Department Chair Patrick Woolley, Associates Hillary E. Maynard, Megan Hart and Hyeok “Jae” Lee, as well as Paralegals Latoya Jenkins and Kheon Hendricks.